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X series of nonpcptidic human rcnin inhibitors with a 4-mcthoxymcthoxypipcridinylamide at the P4 position of the n~oIcculc exhibited slow tight 
binding IO the cnzymc. Rcplaczmcnt of the mcthoxymcthoxy moiety on the pipcridinc ring with H. OH, mcthoxycthyl. propyloxy or rr-butyl 
climinatcd ihc &l&t. The inhibition was partially rcvcrscd by prolonged dialysis at 4°C. arguing against formation of a covalent bond in the 
tightcncd complex. 
Human rcnin; Enzyme inhibition; Slow binding 
1. INTRODUCTION 2. MATERIALS AND METHODS 
In the continuing scar& fol mnibitors of lluman 
renin which are bioavailable by the oral route of ad- 
ministration. a series of nonpcptidic molecules possess- 
ing a 4-mcthoxymethoxypipcridinylam’de group at the 
corresponding ?4 position of angiotcnsinogcn was syn- 
thesized [I]. During some routine studies we observed 
that the compounds exhibited slow tight binding prop- 
erties in that the degree of inhibition increased as the 
prcincubation time of inhibitor with rcnin was in- 
crcascd. Such behavior has not been rcportcd previ- 
ou:ly for rcnin inhibitors. although it has been seen with 
other protcinascs and pcptidascs uch as pepsin [31 and 
angiotcnsin converting cnzymc [3]. 
Represcntativc mcmbcrs of this scrics have been 
found to be bioavailable orally in animals [4.5] and 
conscqucntly may kc viable candirl;~tcs for the trcat- 
mcnt of hypcr:cnsion and congestive heart IYurc in 
man. It is cxpcctcd that rcnin inhibitors will pusscss the 
same thcrapcutic profile as the ungiolcnsin converting 
rntymc inhibitors yet will oll’cr the potential for a lcsscr 
incidence of side cffccts due to the rcmarkablc spcci- 
fcity of renin for its only known substrate. angiotcnsi- 
nogcn [6]. In order to gain additional insight into Ihe 
inhibitory propcrtics of this class of compounds prior 
to clinicill cvi~lualion. WC probed the 4’fifct of modifying 
the 4-mcthl)xymcthoxy substitution on the inhibition, 
The synthesis of the nonpcptidic rcnin inhibitors has been rcportcd 
171. In brief. the appropriate 4-substitulcd pipcridinc was reacted with 
L-phcnyllactic acid utilizillg general pcptidc coupling conditions. The 
resulting amide was alkylatcd with d-2-bromohcxanoic acid 10 form 
the Z(S)-atkauyzcid. which was then reacted with (i) 2(S)-rmino-l- 
cyclohcxyl-3~R1.3~S)-dihydroxy-6-mcthylhcptane lo yield corn- 
pounds: 1. 5. 6. 7.8 and 9, or (ii] I(S!-amino-l-cyclohcxyl-?(R)- hy- 
dmxy-S(S)-:(dimcthylamino cthoxycarbonylhmino: -f-mclhglhcp- 
lime IO yield 4 or (iii) l-(S)-amInc-‘-cyclohcxyl-.1(S~-hSclrox~-hlS1- 
n-butylvarbamoyl-6.mcthylhcpranc 10 yield 2. Compound 3 ur\ prc- 
pared in it similar m.:nncr liom 4-mclhonymcthoxy pipcridinc and 
CBZ-phcnylalaninc forming the nitrugcrr analog of the ?(S)-;rlko- 
xyacid dcscribcd ;tbnvc. follou<d by convcr\ion 10 the duGed prcducr 
as in (ii). 
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3. RESULTS AND DISCUSSION 
Ic,vallu!s aud m of four represfxuative com- 
pounds, l-4. are shown in Table I. Each of the inhi- 
bitors exhibited low nanomolar potency in the purified 
system at pH 6.0. Although the potency decmased in 
plasma at pH 7.4. the K, values uere still in the S-13 
nM range. 
The efkt of preincubation time on the percent in- 
hibition of tin in the purified system is shown in Table 
II, It can lx seen that each of the compounds caused 
progressiveIy greater iuhibition as the preincubation 
time was ~IWEZWA The IC, values decreased accord- 
in& by factors of 6-10. at 30 min compared to the 1 .O 
minute data. IC, valm in plasma at pH 7.4 were even 
more timedependent as illustrated in Table 111. The 
potencies increased from 1 l- to 3E-fold. as the reaction 
time for the generation of angiotensin I was increased 
from IO min to 240 min. 
The time-dependent inhibitions observed could not 
bc caused by an artifact arising from depletion of inhib- 
itor as a consequence of binding to the rcnin. The IC,, 
value of the most potent inhibitor. 1, in the purified 
system was greater than the renin concentration utiti 
in the test by a factor of 16; in plasma. the lowest IC,, 
values were of the order of 50 tim greater than the 
concentration of renirn. 
The requirement of the intact 4-methoxymcthoxy 
group for slow binding is illustrated with the com- 
pounds in Table IV. Replaccmect with H, OH. 
CH,OCH:CH~, CH,CH,CH,O, or CH&.ZH,), in each 
case rewhed in the !cxz of the promy as demonstmtcd 
by tbe bek of increase in inhibition as the time in- 
0 
0 
NH 
0 
OH CtI, 
\-A/&“, l-O I3 
1 
2.9 8.3 
a3 
4 
creased; the reason for this behavior is not known. If 
some type of slow process were occurring with these 
compounds. it was completed within 1 min inasmuch as 
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Table Ill 
Effect of incubation time on the magnitude of rcnin inhibition in 
• human plasma~ 
• Compound IC~o (nMI Human plasma, pH 7,4 (rain) 
l 0* 120 240 
! l iO 13 l0 
2 83 8.2 6.4 
3 95 8.7 3.0 
4 86 9.8 6.5 
*supplemented with purified human renal renin {see section 2) 
Table V 
Reactivation of inhibited renin by prolonged ialysis at 4~C 
Reactivation lime (h) % Initial activity 
pH 6.0 pH 7.4 
0 0.0 15 
76 5.5 22 
t20 10 34 
I60 16 58 
Inactivation - 2 h, 37°C, 10 nM renin and I. Activation - 400 ml in 
pierce microdialyzer. 4°C pH 6.0 {maleate) or pH 7.4 (HEPES}. 
the percent inhibit ion was unchanged (except for the 
n-butyl derivative), within experimental error,  for  each 
of  the modif ied compounds  as the pre incubat ion time 
was increased f rom 1 min to 30 rain. A possible mecha- 
nism for these observat ions might stem f rom the be- 
havior  o f  the 2 oxygen atoms in the methoxymethoxy  
side chain. The first interaction might involve a loose 
association o f  one oxygen atom with histidine-287 in the 
rcnin molecule; molecular  modeling studies with inhibi- 
tor 2 and the enzyme revealed that the methoxymethoxy  
side chain was within hydrogen binding distance of  
His 287 [13]. The second oxygen atom might be required 
for a stronger bonding resulting f rom a consequent al- 
Iosteric modif icat ion of  the enzyme. Studies are con- 
tinuing in an  effort to gain addit ional  insight into the 
phenomenon.  
That  the renin-inhibitor complex could  be dissoci- 
ated by dialysis with the resultant generat ion o f  active 
renin and removal  o f  the inhibitor was demonstrated 
with compound 1. The results obtained,  summarized in 
Table  V. show that prolonged dialysis o f  the tightened 
complex at 4°C resulted in the regeneration of  renin 
Table 1N? 
Loss of slow, fight binding property with modification of methoxymethoxy group 
o 
R Concentration, M 
Renin,Inhibition. % 
Renin - Inhibitor Preineubation Time, Min 
I 5 30 
I Cf130CI120 1.0 X 10 .9 23 41 76 
5 II 2.4 X 10 8 49 54 49 
6 lie !,3 X 10 .7 37 37 37 
7 CIJ3OCH2Ctt2 1.8 X 10 .8 66 60 65 
8 C||3C;t2CII20 2.9 X 10 -s 72 7~ S0 
9 Cit3(CI12)2Cll2 1,0 X 10 "6 50 45 31 
31)3 
The FoniEatiorr qfa tightened xnin-inhiiitor complex 
may haw thempeutic impliciti& for this ckw of non- 
peptidicinhiiitors. An kpected consequence would be 
an extended duration’ of action since once formed. the 
complex w&Id &ease less train than one subject to 
conventional competitive inhibition. Reversal was more 
easily accomplished at phyio@ical pH, however. so it 
is difktdt to predict how the prom will be mani- 
ftied in viva. The eva!uation of the 0vemU eikx awaits 
detailed phannaccllo~cal studk with specific com- 
poUfld5. 
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